BCC Research reports that artificial intelligence is expanding investment and commercialization opportunities across bioprinting and blood cancer therapeutics, while a separate market study projects global blood cancer therapeutics revenue will rise from $70.8 billion in 2024 to $125.5 billion by 2030 at a 10.2% CAGR from 2025 to 2030. In bioprinting, corporate AI investment reached $252.3 billion in 2024, private investment rose 44.5% year over year, mergers and acquisitions increased 12.1% and overall investment grew more than 13-fold since 2014. The U.S. led private AI investment with $109.1 billion, compared with $9.3 billion in China. Venture financings included Aspect Biosystems' $115 million Series B in January 2025, Morphocell Technologies' $50 million Series A and Cellino Biotech's $25 million ARPA-H award. In blood cancer therapeutics, North America accounts for 52.4% of global market revenue in the broader market forecast and more than 40% of AI-based market share in the AI-focused report. The top 50 pharmaceutical companies increased R&D spending by nearly 60% between 2012 and 2022 to approximately $167 billion in 2022. AI commitments included approximately $500 million from Exscientia, approximately $400 million from Insilico Medicine and $400 million from XtalPi, while Sanofi deployed $300 million to integrate real-world oncology data and its Insilico collaboration has a headline value of $1.2 billion including R&D milestones and tier-based royalties. Predictive models can reduce clinical trial durations by up to 50%, deep-learning systems classify leukemia subtypes with over 97% accuracy, digital pathology platforms including Harvard's CHIEF and PathAI identify mutations through virtual sequencing with 94%–96% accuracy, and biomarker tools identify markers such as PD-L1 expression and Tumor Mutational Burden with 85%–95% accuracy. Emerging treatments include CAR T-cell therapies such as Breyanzi and Abecma, BiTE antibodies such as BLINCYTO, antibody-drug conjugates including Trodelvy, POLIVY and ADCETRIS, second-generation BTK inhibitors such as Calquence and first-in-class protein degraders targeting AML. Key risks include privacy and compliance costs, fragmented data, model updates, drug resistance, biosimilar competition, reimbursement complexity, accelerated-approval scrutiny and uneven access in developing markets.